Background
Laryngeal carcinoma, of which the majority is laryngeal squamous cell carcinoma, is the second most common cancer of the human head and neck worldwide. About 60% of patients with this disease were in advanced stage upon diagnosis, with 5-year survival around 65% [ 1 ]. Tobacco use and alcohol consumption are the 2 major risk factors linearly associated with the occurrence of laryngeal carcinoma [ 2 , 3 ]. Accumulating evidence shows that the larynx is one of the sites most vulnerable to infection by human papillomavirus (HPV) [ 4 , 5 ]. Therefore, HPV infection could be an emerging risk factor for the development of laryngeal carcinoma [ 6 , 7 ]. However, Xu et al. recently showed that HPV infection in Asian patients did not account for the occurrence of laryngeal carcinoma, indicating that patients’ racial disparities could be another determinant of HPV-mediated laryngeal carcinoma [ 8 ]. Traditionally, surgical therapy plus radiotherapy are the main treatments for patients with laryngeal carcinoma [ 9 ]. Potential voice loss and extensive rehabilitation after oncologic larynx surgery may be detrimental to a patient’s quality of life. Thus, novel therapeutic approach to effectively restrict the neoplasm growth are urgently needed by patients with laryngeal carcinoma, especially for those with earlier diagnosis.
Interferon (IFN) is a cytokine with potent antiviral, anti-proliferative, and immuno-modulatory capacity [ 10 ]. The human type I IFN includes 17 members: 13 alpha subtypes, as well as 1β, 1ɛ, 1κ, and 1ω, which are all located on human chromosome 9 [ 11 – 13 ]. All these IFNalpha subtypes recognize the same receptor molecule, the type I IFN receptor (IFNAR), indicating that the distinct function of each subtype is retained during evolution. The binding of the IFN molecule to its specific receptor activates the intracellular signaling pathway, especially the JAK/STAT pathway, which can drive hundreds of downstream interferon response gene (ISG) expressions. It has been shown that the anti-proliferative effect of IFNalpha could result in cell apoptosis. However, the mechanism is still not well defined. Some studies have shown that a number of the ISGs can promote cell apoptosis by upregulating the expressions of the key pro-apoptotic genes [ 14 – 16 ]. However, IFNalpha-mediated cell apoptosis is not observed in every tissue examined, indicating that IFNalpha-mediated cell apoptosis may function in a tissue-specific manner.
There are 2 well-known pathways responsible for cell apoptosis: the intrinsic and extrinsic cell death pathways. The intrinsic mitochondrial pathway is controlled by the Bcl-2 family proteins, with pro-apoptotic and anti-apoptotic properties. A ‘point of no return’ occurs when an arrived death signal enhances the permeabilization of the mitochondrial outer membrane, which in turn promotes the release of cytochrome c into the cytosol. Activation of the extrinsic apoptotic pathway is marked by cleavage of caspase 8 and caspase 10 in the cytosol. The intrinsic and the extrinsic cell death pathways converge on the activation of the final executioners, caspase 3 and 7. Subsequently, the activated caspase 3 inactivates the highly reliable apoptotic biomarker, PARP1, by cleaving it between Asp214 and Gly215 to further promote apoptosis. In addition, endoplasmic reticulum (ER) stress is a normal cellular response to unfolded proteins by different exogenous and endogenous stimulators. However, prolonged ER stress can induce cell apoptosis due to the accumulations of unfolded or mis-folded proteins. The hallmark of ER stress-mediated apoptosis is the activation of caspase 12 in mice or the activation of caspase 4 in humans, which can subsequently induce the cleavage of caspase 3/7 [ 17 , 18 ].
In this study, we first demonstrate that the anti-proliferative effect of IFNalpha-1a on human laryngeal carcinoma HEp-2 cells is directly linked to the IFNalpha-1a-mediated cell apoptosis. Our mechanism study demonstrates that IFNalpha-1a markedly inhibits cell proliferation by activating the intrinsic and ER stress-mediated apoptotic pathways. In addition, microarray and pathway analysis revealed the top differential genes and the major pathways that respond to IFNalpha-1a treatment. Our study reveals a previously undefined role for IFNalpha-1a in promoting apoptosis of laryngeal carcinoma cells.
Material and Methods
Antibodies and reagents
Anti-HA antibody was from Huaxingbio (Beijing, China); anti-caspase3 antibody was from Cell Signaling Technology (Danvers, MA, USA); anti-caspase 8, anti-caspase 4, anti-cleaved-caspase 3, anti-Bcl-XL, anti-cleaved caspase 8, anti-cytochrome C, anti-CHOP, anti-PARP1, and anti-GRP78 antibodies were all purchased from Proteintech Group, Inc. (Rosemont, IL, USA); anti-caspase 10 antibody was from Bioworld Technology, Inc. (St. Louis Park, MN, USA); anti-β-actin antibody was from Transgen Biotechnology (Beijing, China); anti-GAPDH antibody was from Affinity Biosciences (Cincinnati, OH, USA). Human recombinant IFNalpha-1a was purchased from ProSpec-Tany TechnoGene (Ness Ziona, Israel). Cell counting kit-8 was from Dojindo (Kumamoto, Japan).
The isolation of IFNalpha-1a cDNA and the construction of IFNalpha-1a expression plasmid
The full length of IFNalpha-1a coding sequence was isolated from the total RNAs of human embryonic brain tissue using the forward primer 5′-TTAAGCTTATGGCC TCGCCCTTTGCTTTA-3′ and the reverse primer 5′-TTGAATTCCTAAGCGTAGTC TGGGACGTCGTATGGGTATTCCTTCCTCCTTAATCTTT-3′. After reverse transcription, the reaction product was amplified by polymerase chain reaction (PCR) as follows: denaturation at 94°C for 5 min, then amplification at 94°C/30 s, 55°C/30 s, and 72°C/2 min for 35 cycles. The reaction product was finally extended at 72°C for 10 min. The PCR products were separated and extracted from agarose gel. The IFNalpha-1a cDNA that carries the coding sequence of influenza hemagglutinin (HA) epitope tag was first subcloned into pMD18T-Simple vector to form pMD18T-Simple-IFNalpha-1a-HA construct. After confirmation by sequencing analysis, IFNalpha-1a-HA was released from pMD18T-Simple-IFNalpha-1a-HA by EcoRI/HindIII double-digestion and subsequently subcloned into the EcoRI/HindIII sites of pcDNA3.0 to form pcDNA3.0-IFNalpha-1a-HA construct.
Cell culture, transient transfection, and cell treatment
The human laryngeal squamous cancer cell line HEp-2 cells, human embryonic kidney HEK293T cells, human hepatocellular carcinoma HepG2 cells, and human lung carcinoma A549 cells were obtained from the Cell Culture Center of the Basic Institute of Medical Sciences, Chinese Academy of Medical Sciences (Beijing, China). Hep-2 cells were grown in DMEM (Gibco) supplemented with 10% fetal bovine serum at 37°C with 5% CO 2 . At about 80% confluency, Hep-2 cells were transiently transfected with increasing doses of plasmid pcDNA3.0-IFNalpha-1a-HA DNAs by NeoFect (Neofect biotech Co, Beijing, China) according to the instruction manual. Hep-2 cells were also treated with increasing doses (0, 50, or 200 ng/mL) of IFNalpha-1a for 48 h before harvesting.
Cell proliferation assays
Cell proliferation potentials were evaluated by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and cell counting kit-8 (CCK-8) tests. The HEp-2 cells grown on a 12-well culture plate were either transiently transfected with pcDNA3.0-IFNalpha-1a plasmid DNAs or treated with IFNalpha-1a for 48 h. For CCK-8 assay, the transfected HEp2 cells were treated with CCK8 reagent for 2 h before detection using a microplate reader at 490 nm. Cell proliferation potentials were assessed by CCK-8 based on the standard curve of optical density and cell number. For MTT assay, the transfected Hep-2 cells seeded onto 96-well microtiter plates were treated with IFNalpha-1a before testing. After addition of MTT reagent, HEp-2 cells continued to culture for 2 h. Then, the culture medium was discarded and the purple crystal formazan was dissolved by DMSO. Finally, the optical density was detected using a microplate reader at 450 nm.
Apoptosis assay
Cell apoptosis was detected using an Annexin V-FITC apoptosis detection kit (Biotool, Beijing, China). Briefly, the transiently transfected or IFNalpha-1a-treated HEp-2 cells were harvested after 48-h incubation. The cell pellet was resuspended with 100 μL of 1×binding buffer, followed by adding 5 μL Annexin V-FITC and 5 μL propidium iodide (PI). The reaction mixture was incubated away from light for 15 min at room temperature. Then, another 400 μL 1X binding buffer was added into the mixture. The reaction product was subjected to flow cytometric analysis using an Accuri C6 device (BD Biosciences, San Jose, CA, USA).
Western blot analysis
The transiently transfected or IFNalpha-1a-treated HEp-2 cells were lysed with ice-cold lysis buffer (1% NP-40, 50 mM Tris-HCl (pH 7.5), 120 mM NaCl, 200 μM NaVO4, 1 μg/mL leupeptin, 1 μg/mL aprotinin, and 1 μM PMSF) for 30 min at 4°C. About 10 μg of cell lysates was separated on 12% SDS-PAGE. The resolved proteins were transferred to nitrocellulose membranes (Amersham Biosciences, Freiburg, Germany). The membrane was incubated with a primary antibody followed by a horseradish peroxidase-conjugated secondary antibody. The protein bands were developed with Novex ECL Western Blotting substrate (Invitrogen, Thermo Fisher Scientific, USA). The Chemiluminescence image was captured om a Tanon Luminescent imaging workstation (YPH-Bio, Beijing, China).
Microarray analysis
Total RNA was extracted from HEp2 cells using Trizol reagent before being assessed in the microarray experiment. Affymetrix GeneChip ® Human Transcriptome 2.0 Arrays analysis was conducted using the GeneChip ® WT Plus Reagent Kit according to the manufacturer’s instructions (GeneChip ® WT PLUS Reagent Kit Manual Target Preparation for GeneChip ® Whole Transcript (WT) Expression Arrays P/N 703174 Rev. 2, 2013). Briefly, the first-strand cDNA was synthetized from 500 ng of RNA using Superscript II reverse transcriptase primed with a poly(T) oligomer that was driven by T7 promoter. The second-strand cDNA synthesis was followed by in vitro transcription amplification. The obtained cRNA was used as a template for a second cDNA synthesis cycle with dUTPs incorporated into the new strand. Uracil-DNA glycosylase and purin-pyrimidin endonuclease were used to fragment the cDNA. The fragments were biotin-labeled and then hybridized against arrays. The arrays were stained, washed, and scanned after 16 h of hybridization. TAC was used to analyze the chip data. Screening of differentially expressed genes was by multiple differential method (Fold change=2 experiment group_NS−control group_NS ) based on the fold change (FC) ≥2, or fold change ≤–2 ( p <0.05).
Reverse transcription-polymerase chain reaction (RT-PCR)
Both semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) and quantitative real-time RT-PCR (qRT-PCR) were employed to validate the selected gene expressions of IFNalpha-treated Hep2 cells. Total RNAs were extracted from the cultured cells with TRIzol (Invitrogen, Carlsbad, CA, USA). The purified total RNAs were treated with DNase I (Qiagen, Dusseldorf, Germany). All primers used in RT-PCR and qRT-PCR are summarized in Table 1 . The RT-PCR reaction was carried with a PrimeScript One-Step RT-PCR Kit (Takara Biotechnology, Dalian, China) by following the manual instructions. The RT-PCR was carried out in DNA Thermal Cycle (Applied Biosystems, Carlsbad, CA, USA) as follows: 50°C for 35 min for reverse transcription; 94°C for 5 min for denaturing; PCR condition was 94°C for 30 s, 50°C for 30 s, 72°C for 50 s, and repeated for 20 cycles; the reaction was extended at 72°C for 10 min before being stored at 4°C. One-step real-time quantitative RT-PCR (qRT-PCR) (Takara Biotechnology, Dalian, China) was also performed according to the instruction manual with the CFX real-time PCR detection system (Bio-Rad Laboratories, Hercules, CA, USA) as follows: 42ºC for 5 min and 95ºC for 10 s; 95ºC for 5 s, and 60ºC for 10 s, and repeated for 40 cycles. The dissociation of the reaction products was conducted at 55–95ºC, as the temperature rose at 0.2ºC per 10 s.
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis
KEGG pathways enrichment analysis is based on the gene and genomic encyclopedia of molecular interaction, reaction, and relation networks [ 19 ]. The Database for Annotation, Visualization and Integrated Discovery (DAVID) [ 20 ] bioinformatics web ( http://david.abcc.ncifcrf.gov/summary.jsp ) was utilized to identify KEGG pathways that are enriched with IFNalpha-1a treatment. The DAVID 6.8 program was used to analyze differentially expressed genes at a significance level.
Statistical analysis
Data are presented as mean ± standard deviation (SD) from at least 3 independent experiments and subject to 2-tailed, unpaired t test. A p value less than 0.05 was considered statistically significant.
Results
IFNalpha-1a inhibits the proliferation potential of laryngeal carcinoma Hep-2 cells
It has been known for many years that IFNalpha can serve as a therapeutic agent for the treatment of human laryngeal carcinoma [ 21 ]. However, how IFNalpha exerts its anti-proliferative effect on human laryngeal carcinoma is largely unclear. To address this issue directly, HEp-2 cells were used as a test model of laryngeal cancer for IFNalpha-1a treatment. We hypothesize that IFNalpha-1a might induce the anti-proliferative effect on HEp-2 cells. Two strategies were employed to test this hypothesis: one uses transient transfection approach and the other uses the exogenous delivery of recombinant human IFNalpha-1a into HEp-2 cells. The full-length of coding sequence (cDNA) of IFNalpha-1a was cloned from human fetal brain mRNAs by RT-PCR analysis. After sequencing confirmation, IFNalpha-1a cDNA was subcloned into pcDNA 3.0 to form eukaryotic expression vector pcDNA 3.0-IFNalpha-1a. The plasmid pcDNA 3.0-IFNalpha-1a DNAs were then transiently transfected into HEp-2 cells. Both MTT and CCK-8 results ( Figure 1A, 1B ) demonstrate that the cell proliferative potentials of HEp-2 cells were significantly inhibited by pcDNA 3.0-IFNalpha-1a. To further consolidate the result, HEp-2 cells were also treated with exogenously delivered recombinant IFNalpha-1a. Figure 1C and 1D demonstrate that the increased delivery of the recombinant IFNalpha-1a into HEp-2 cells markedly inhibited cell proliferation, further confirming that IFNalpha-1a has an anti-proliferative effect on human laryngeal carcinoma cells.
IFNalpha-1a induces apoptosis of laryngeal carcinoma HEp-2 cells
Sustained inhibition of cell proliferation leads to apoptosis of targeted cells. IFNalpha-1a-mediated anti-proliferation of HEp2 cells may induce cell apoptosis. To test whether IFNalpha-1a promotes apoptosis of HEp-2 cells, flow cytometric analysis by Annexin V/PI double staining was employed. Significant apoptosis was detected as the transfected dose of pcDNA 3.0-IFNalpha-1a increased ( Figure 2A, 2B ). To further confirm the results, HEp-2 cells were also treated with exogenous recombinant human IFNalpha-1a. Consistent with the results of the transient transfection experiment, the increased delivery of the recombinant IFNalpha-1a into HEp-2 cells dramatically promoted apoptosis of the targeted cells ( Figure 2C, 2D ), indicating that IFNalpha-1a induces apoptosis of human laryngeal carcinoma HEp-2 cells.
The effect of IFNalpha-1a on the apoptosis of other cell types
The next question that we attempted to ask was whether IFNalpha-1a treatment leads to apoptosis of other cell types. To address this question directly, 3 human cell lines (transformed human embryotic kidney HEK293T cells, human hepatocellular carcinoma HepG2 cells, and human lung carcinoma A549 cells) were selected for the treatment of IFNalpha-1a. Flow cytometric analysis by Annexin V/PI double staining was performed. The increased delivery of pcDNA 3.0-IFNalpha-1a into HEK293T ( Figure 3A ), HepG2 ( Figure 3B ), and A549 ( Figure 3C ) by transient transfection did not induce significant apoptosis in the respective cell lines. IFNalpha-1a-mediated apoptosis failed to be induced after the exogenous delivery of recombinant IFNalpha-1a into the cell culture medium of HEK293T ( Figure 3D ) and A549 ( Figure 3F ) but not HepG2 cells ( Figure 3E ), indicating that IFNalpha-1a-mediated apoptosis might function in a cell/tissue-specific manner.
IFNalpha-1a activates the intrinsic but not extrinsic apoptotic pathway
The intrinsic and extrinsic apoptotic pathways are 2 well-defined apoptotic pathways in mammal cells. To detect which pathway is activated by IFNalpha-1a, Western blot analysis was performed to examine the activation status of the key mediators in each pathway. First, HEp-2 cells were transiently transfected with increasing doses (0, 0.5, and 3.0 μg) of pcDNA 3.0-IFNalpha-1a. Overexpression of IFNalpha-1a dramatically inhibited the expression of the anti-apoptotic protein B cell lymphoma-XL (Bcl-XL), increased the cytoplasmic distribution of cytochrome c, and promoted the cleavages of caspase 3 and poly(ADP-Ribose) polymerase 1 (PARP1) dose-dependently ( Figure 4A ), indicating that the cell-intrinsic apoptotic pathway was activated. In contrast, increased delivery of pcDNA 3.0-IFNalpha-1a into HEp-2 cells failed to promote cleavages of caspase 8 and 10 ( Figure 4B ), indicating that IFNalpha-1a-mediated apoptosis is independent of the extrinsic apoptotic pathway. To further confirm the above results, HEp-2 cells were also treated with increasing doses (0, 50, and 200 ng/mL) of recombinant IFNalpha-1a. In agreement with the results of transient transfection, the addition of exogenous IFNalpha-1a decreased Bcl-XL expression, enhanced the expression of cytochrome c, and activated the cleavage of caspase 3 and PARP1 ( Figure 4C ), but had no effects on the expressions of caspase 8 and caspase 10 ( Figure 4D ), demonstrating that IFNalpha-1a indeed activates the intrinsic but not extrinsic apoptotic pathway.
IFNalpha-1a induces endoplasmic reticulum stress-related apoptosis
In addition to intrinsic and extrinsic apoptotic pathways, we investigated a third apoptotic pathway named endoplasmic reticulum (ER) stress-associated apoptosis. Sustained ER stress usually triggers cells to undergo apoptosis. During ER stress, the expression of ER stress response genes (GRP78, CHOP and ATF4) is upregulated, and the activation of human caspase 4 is directly associated with ER stress-mediated cell apoptosis. To detect whether ER stress-mediated apoptosis can be induced by IFNalpha-1a, HEp-2 cells were either transiently transfected with pcDNA 3.0-IFNalpha-1a or treated with exogenous recombinant human IFNα-1a. Figure 5A and 5B show that the increased delivery of either pcDNA 3.0-IFNalpha-1a or recombinant IFNalpha-1a dramatically enhanced the expressions of GRP78 and CHOP and markedly promoted the activation of caspase 3 and caspase 4, indicating that IFNalpha-1a indeed promotes ER stress-mediated apoptosis.
Microarray and pathway enrichment analysis of the gene expression profiles of IFNalpha-1a-treated HEp-2 cells
The results of microarray revealed that, under stringent criteria, 1236 upregulated and 531 downregulated probe sets displayed differential expressions by at least 1.5-fold. The top 40 differentially expressed genes that have been characterized are shown in Table 2 . Among them, several IFN-alpha-regulated genes were dramatically upregulated, such as interferon alpha-inducible protein 6 (IFI6, 1228 folds), IFI27 (236 folds) and interferon-induced protein 44-like (IFI44L, by 18.25-fold), while the top down-regulated genes include DNA-activated catalytic polypeptide (PRKDC, −8.86 folds), histone cluster 1 H3b (HIST1H3B, by −6.51 fold), dynein cytoplasmic 1 heavy chain 1 (DYNC1H1, by −4.57 fold), histone cluster 1, H2am (HIST1H2AM, by −4.56 fold), and activating transcription factor 6 (ATF6, by −4.51 fold). The results of microarray analysis were validated with both semi-quantitative RT-PCR ( Figure 6 ) and qRT-PCR ( Figure 7 ) approaches on 3 selected upregulated genes (IFI6, IFI27, and IFI44L) and 3 selected downregulated genes (PRKDC, DYNC1H1, and ATF6).
Pathway enrichment analysis is an effective approach to identify the potential key cellular pathways for high-throughput data. Here, the identified top 40 genes were formatted and subjected to analysis with the DAVID Bioinformatics program. The results of the KEGG pathway data set revealed that IFNalpha-1a-treated HEp2 cells were enriched in at least 6 KEGG pathways ( Table 3 ). Four out of 6 pathways are associated with TP53: they are pathways in cancer ( p =0.011), transcriptional mis-regulation in cancer ( p =0.020), MAPK signaling pathway ( p =0.032), and small cell lung cancer ( p =0.046). The 2 TP53 unrelated pathways are calcium signaling pathway ( p =0.027) and signaling pathways regulating pluripotency of stem cells ( p =0.043). Therefore, the results also suggest that the TP53-related pathways might be involved in IFNalpha-1a-mediated HEp-2 apoptosis.
Discussion
Laryngeal cancer is one of the most common head and neck carcinomas. Surgical therapy and chemo-radiation treatment are the 2 major therapeutic choices for laryngeal cancer patients. However, both treatments can be associated with some severe adverse effects such as voice loss [ 9 ] and toxicity [ 22 ]. Thus, novel therapeutic strategies are urgently needed [ 10 ]. Our current results demonstrate that overexpression of IFNalpha-1a cDNA or addition of recombinant IFNalpha-1a significantly promotes both intrinsic and ER-stress-mediated apoptosis in HEp-2 cells, indicating that IFNalpha-1a may provide a therapeutic alternative for laryngeal cancer patients in the future.
Interferon exerts its antineoplastic property by either serving as an immunological modulator to promote cancer-specific immune responses or functioning as an anti-proliferative agent to block tumor growth. Xu et al. showed that using mesenchymal stem cells (MSC) as a carrier to deliver IFNalpha (MSC-IFNalpha) into tumor tissue failed to induce an anti-tumor effect in immunodeficient mice, but MSC-IFNalpha-mediated anti-tumor activity could be dramatically enhanced in immune-competent mice, indicating the immuno-dependent character of MSC-IFNalpha treatment in vivo [ 23 ]. IFN has been regarded as an indirect mediator that exerts its anti-proliferative effect by upregulating the expressions of pro-apoptotic ISGs [ 24 ]. For example, inositol hexosephosphate kinase 2 (IP6K2)/interferon-induced death (RID) is an IFNβ-stimulated gene that promotes apoptosis of ovarian cancer cells [ 25 ]. Subsequent studies showed that the upregulation of IP6K2/RID expression is directly linked to p53-mediated apoptosis through the DNA-PK/ATM-p53 cell death axis [ 26 , 27 ]. Our study revealed the mechanisms of IFNalpha-1a-mediated apoptosis in HEp-2 cells by which both intrinsic and ER-stress-mediated apoptotic pathways are activated. However, it remains unclear how IFNalpha-1a stimulates these 2 apoptotic pathways in HEp-2 cells. IFN-induced cell apoptosis has been shown to occur indirectly through apoptotic mediators such as ISGs [ 24 , 28 ]. Nevertheless, the pro-apoptotic ISGs specifically induced by IFNalpha-1a are still unknown and need to be further investigated. Therefore, we cannot exclude the possibility that IFNalpha-1a promotes intrinsic and ER-stress-mediated cell apoptosis through a direct mechanism.
In 1986, recombinant IFNalpha-2a and IFNalpha-2b were the first 2 cytokines to be licensed for the treatment of hairy cell leukemia in the United States [ 29 ]. Since then, IFNalpha-2 has been primarily used for the treatment of various blood cancers such as chronic myelogenous leukemia [ 30 ], non-Hodgkin lymphomas [ 31 , 32 ], and multiple myeloma [ 31 – 33 ], as well as some virus infections such as chronic hepatitis B viral (HBV) infection [ 34 ] and chronic hepatitis C viral (HCV) infection [ 35 ]. IFNalpha-2 has become the preferred therapeutic molecule approved by the US Food and Drug Administration (FDA) for treatment of certain cancers and infectious diseases [ 10 , 36 , 37 ]. The reason for this preferred use of IFNalpha-2 subtype in clinic is elusive. One possibility might be that IFNalpha-2a and 2b were the first 2 IFN molecules to be cloned and characterized with higher activity and potency – 10-fold more potent than IFNalpha-1b, as measured by antiviral activity [ 38 ]. In 1997, the recombinant IFNalpha-1b was approved for treatment of chronic hepatitis B and C in China [ 38 ]. Although the clinical effect and toxicity of IFNalpha-1b have been evaluated in cancer patients [ 38 ], IFNalpha-1 has not been approved for use as a therapeutic drug to treat human cancers in clinical practice. It has been shown that IFNalpha-1 has lower anti-proliferative and antiviral activities compared with other IFNalpha subtypes [ 39 , 40 ]. However, our functional study demonstrated that IFNalpha-1a can induce cell apoptosis in laryngeal carcinoma HEp-2 cells. This may be partly due to the stable ternary complex formed upon the binding of IFNalpha-1a to IFNalpha receptors on HEp-2 cells, which might be critical for the generation of certain pro-apoptotic ISGs in HEp-2 cells.
Microarray analysis reveals several differential genes that are dramatically upregulated after IFNalpha-1a treatment in HEp-2 cells. The 3 most upregulated genes – IFI6, IFI27, and IFI44L – are typical interferon alpha-inducing genes. Studies indicate that IFI6 might be double-edged sword to regulate cell growth versus apoptosis. Earlier reports have defined IFI6 as an anti-apoptotic gene that promotes melanoma development [ 39 ] and facilitates viral infection [ 40 ]. In contrast, Li et al. recently found that a short spliced variant of CTCF (CTCF-s) could up-regulate IFI-6 expression by competing with CTCF binding at the IFI6 promoter region, which subsequently induces cell apoptosis [ 41 ]. The effect of CTCF-s has great similarity to that of IFNalpha-1a. This is because, in addition to IFI6, CTCF-s like IFNalpha-1a can also upregulate IFI27 and ISG15 expressions [ 41 ]. IFI27 has been shown to stimulate cell apoptosis by promoting mitochondrial membrane destabilization [ 42 ], while IFI44L has a tumor-suppressor effect [ 43 ]. Therefore, upregulating IFI6, IFI27, and IFI44L gene expressions should facilitate IFNalpha-1a-mediated cell apoptosis. When cells are undergoing apoptosis, apoptosis-related genes can be induced, but growth-related genes need to be repressed. The downregulated genes discovered by our microarray analysis are indeed associated with cell survival and proliferation. For example, both PRKDC [ 44 ] and HIST1H3B [ 45 ] have been shown to play a regulatory role in apoptotic inhibition and tumor growth. Therefore, downregulating these gene expressions by IFNalpha-1a should promote the apoptosis of HEp-2 cells.
Conclusions
Our study elucidates a previously undefined mechanism for IFNalpha-1a, which could be used to induce apoptosis of certain cancer cells, such as laryngeal carcinoma HEp-2 cells, via both intrinsic and ER-stressed apoptotic pathways. However, more research is needed to determine how the IFNalpha-1 molecule can serve as effective inducer of apoptosis.
Source of support: The study is supported by grant from CAMS Innovation Fund for Medical Sciences (2017-I2M-3-007)
Conflicts of interest
None.
References
1 Siegel RL Miller KD Jemal A Cancer statistics, 2016 Cancer J Clin 2016 66 7 30 10.3322/caac.21332 26742998
2 Kuper H Boffetta P Adami HO Tobacco use and cancer causation: Association by tumour type J Intern Med 2002 252 206 24 12270001 10.1046/j.1365-2796.2002.01022.x
3 Boffetta P Hashibe M Alcohol and cancer Lancet Oncol 2006 7 149 56 16455479 10.1016/S1470-2045(06)70577-0
4 Sanchez Barrueco A Gonzalez Galan F Lora Pablos D HPV in larynx squamous cell carcinoma: New serotypes and survival study within 10-year follow-up Otolaryngol Head Neck Surg 2017 156 677 82 28322111 10.1177/0194599817695545
5 Vietia D Liuzzi J Avila M Human papillomavirus detection in head and neck squamous cell carcinoma Ecancermedicalscience 2014 8 475 25374623 10.3332/ecancer.2014.475 PMC4208923
6 Tsimplaki E Argyri E Sakellaridis A Oropharyngeal and laryngeal but not oral cancers are strongly associated with high-risk human papillomavirus in 172 Greek patients J Med Virol 2017 89 170 76 27335246 10.1002/jmv.24614
7 Weiss D Heinkele T Rudack C Reliable detection of human papillomavirus in recurrent laryngeal papillomatosis and associated carcinoma of archival tissue J Med Virol 2015 87 860 70 25650265 10.1002/jmv.24124
8 Xu Y Liu S Yi H Human papillomavirus infection in 674 Chinese patients with laryngeal squamous cell carcinoma PLoS One 2017 9 e115914 10.1371/journal.pone.0115914 PMC4275260 25536405
9 Steuer CE El-Deiry M Parks JR An update on larynx cancer Cancer J Clin 2017 67 31 50 10.3322/caac.21386 27898173
10 Antonelli G Scagnolari C Moschella F Proietti E Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use Cytokine Growth Factor Rev 2015 26 121 31 25578520 10.1016/j.cytogfr.2014.12.006 PMC7108252
11 Hardy MP Owczarek CM Jermiin LS Characterization of the type I interferon locus and identification of novel genes Genomics 2004 84 331 45 15233997 10.1016/j.ygeno.2004.03.003
12 van Pesch V Lanaya H Renauld JC Michiels T Characterization of the murine alpha interferon gene family J Virol 2004 78 8219 28 15254193 10.1128/JVI.78.15.8219-8228.2004 PMC446145
13 Zwarthoff EC Mooren AT Trapman J Organization, structure and expression of murine interferon alpha genes Nucleic Acids Res 1985 13 791 804 2987810 10.1093/nar/13.3.791 PMC341035
14 Chen L Liu S Xu F Inhibition of proteasome activity induces aggregation of IFIT2 in the centrosome and enhances IFIT2-induced cell apoptosis Int J Biol Sci 2017 13 383 90 28367102 10.7150/ijbs.17236 PMC5370445
15 Stawowczyk M Van Scoy S Kumar KP Reich NC The interferon stimulated gene 54 promotes apoptosis J Biol Chem 2011 286 7257 66 21190939 10.1074/jbc.M110.207068 PMC3044982
16 Tsuno T Mejido J Zhao T BID is a critical factor controlling cell viability regulated by IFN-alpha J Immunother 2012 35 23 31 22130162 10.1097/CJI.0b013e3182372dcf PMC3241910
17 Hitomi J Katayama T Eguchi Y Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death J Cell Biol 2004 165 347 56 15123740 10.1083/jcb.200310015 PMC2172196
18 Nakagawa T Zhu H Morishima N Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta Nature 2000 403 98 103 10638761 10.1038/47513
19 Kanehisa M Furumichi M Tanabe M KEGG: New perspectives on genomes, pathways, diseases and drugs Nucleic Acids Res 2017 45 D353 61 27899662 10.1093/nar/gkw1092 PMC5210567
20 Huang dW Sherman BT Lempicki RA Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists Nucleic Acids Res 2009 37 1 13 19033363 10.1093/nar/gkn923 PMC2615629
21 Haglund S Lundquist PG Cantell K Strander H Interferon therapy in juvenile laryngeal papillomatosis Arch Otolaryngol 1981 107 327 32 6164359 10.1001/archotol.1981.00790420001001
22 Wiegand S Evidence and evidence gaps of laryngeal cancer surgery GMS Curr Top Otorhinolaryngol Head Neck Surg 2016 15 Doc03 10.3205/cto000130 PMC5169076 28025603
23 Xu C Lin L Cao G Interferon-alpha-secreting mesenchymal stem cells exert potent antitumor effect in vivo Oncogene 2014 33 5047 52 24186200 10.1038/onc.2013.458
24 Kotredes KP Gamero AM Interferons as inducers of apoptosis in malignant cells J Interferon Cytokine Res 2013 33 162 70 23570382 10.1089/jir.2012.0110 PMC3624694
25 Morrison BH Bauer JA Kalvakolanu DV Lindner DJ Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-beta in ovarian carcinoma cells J Biol Chem 2001 276 24965 70 11337497 10.1074/jbc.M101161200 PMC2025680
26 Koldobskiy MA Chakraborty A Werner JK Jr p53-mediated apoptosis requires inositol hexakisphosphate kinase-2 Proc Natl Acad Sci USA 2010 107 20947 51 21078964 10.1073/pnas.1015671107 PMC3000257
27 Rao F Cha J Xu J Inositol pyrophosphates mediate the DNA-PK/ATM-p53 cell death pathway by regulating CK2 phosphorylation of Tti1/Tel2 Mol Cell 2014 54 119 32 24657168 10.1016/j.molcel.2014.02.020 PMC4011022
28 El Jamal SM Taylor EB Abd Elmageed ZY Interferon gamma-induced apoptosis of head and neck squamous cell carcinoma is connected to indoleamine-2,3-dioxygenase via mitochondrial and ER stress-associated pathways Cell Div 2016 11 11 27486476 10.1186/s13008-016-0023-4 PMC4969639
29 Golomb HM Ratain MJ Mick R Daly K Interferon treatment for hairy cell leukemia: An update on a cohort of 69 patients treated from 1983–1986 Leukemia 1992 6 1177 80 1434800
30 Talpaz M Kantarjian HM McCredie KB Clinical investigation of human alpha interferon in chronic myelogenous leukemia Blood 1987 69 1280 88 3471281
31 Borden EC Innovative treatment strategies for non-Hodgkin’s lymphoma and multiple myeloma Semin Oncol 1994 21 14 22 7992095
32 Steis RG Foon KA Longo DL Current and future uses of recombinant interferon alpha in the treatment of low-grade non-Hodgkin’s lymphoma Cancer 1987 59 658 63 10822466 10.1002/1097-0142(19870201)59:3+<658::aid-cncr2820591315>3.0.co;2-q
33 Oken MM Kyle RA Kay NE Interferon in the treatment of refractory multiple myeloma: An Eastern Cooperative Oncology Group Study Leuk Lymphoma 1990 1 95 100 27463814 10.3109/10428199009042465
34 Rakela J Wood JR Czaja AJ Long-term versus short-term treatment with recombinant interferon alfa-2a in patients with chronic hepatitis B: A prospective, randomized treatment trial Mayo Clin Proc 1990 65 1330 35 2214880 10.1016/s0025-6196(12)62144-2
35 Zein NN Rakela J Interferon therapy in hepatitis C Semin Gastrointest Dis 1995 6 46 53 7894967
36 Degasperi E Vigano M Aghemo A PegIFN-alpha2a for the treatment of chronic hepatitis B and C: A 10-year history Expert Rev Anti Infect Ther 2013 11 459 74 23627852 10.1586/eri.13.37
37 Di Trolio R Simeone E Di Lorenzo G The use of interferon in melanoma patients: A systematic review Cytokine Growth Factor Rev 2015 26 203 12 25511547 10.1016/j.cytogfr.2014.11.008
38 Paul F Pellegrini S Uze G IFNA2: The prototypic human alpha interferon Gene 2015 567 132 37 25982860 10.1016/j.gene.2015.04.087 PMC5629289
39 Gupta R Forloni M Bisserier M Dogra SK Interferon alpha-inducible protein 6 regulates NRASQ61K-induced melanomagenesis and growth Elife 2016 5 pii: e16432 10.7554/eLife.16432 PMC5031487 27608486
40 Qi Y Li Y Zhang Y IFI6 inhibits apoptosis via mitochondrial-dependent pathway in dengue virus 2 infected vascular endothelial cells PLoS One 2015 10 e0132743 26244642 10.1371/journal.pone.0132743 PMC4526556
41 Li J Huang K Hu G An alternative CTCF isoform antagonizes canonical CTCF occupancy and changes chromatin architecture to promote apoptosis Nat Commun 2019 10 1535 30948729 10.1038/s41467-019-08949-w PMC6449404
42 Cheriyath V Leaman DW Borden EC Emerging roles of FAM14 family members (G1P3/ISG 6-16 and ISG12/IFI27) in innate immunity and cancer J Interferon Cytokine Res 2011 31 173 81 20939681 10.1089/jir.2010.0105 PMC6468951
43 Huang WC Tung SL Chen YL IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway BMC Cancer 2018 18 609 29848298 10.1186/s12885-018-4529-9 PMC5977745
44 Stronach EA Chen M Maginn EN DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance Neoplasia 2011 13 1069 80 22131882 10.1593/neo.111032 PMC3223610
45 Marcussen M Sønderkær M Bødker JS Oral mucosa tissue gene expression profiling before, during, and after radiation therapy for tonsil squamous cell carcinoma PLoS One 2018 13 e0190709 29338018 10.1371/journal.pone.0190709 PMC5770028